What Vicapsys does

Vicapsys Life Sciences, Inc. is a pre-commercial, publicly traded biotechnology company (OTC: VICP) developing localized immunomodulatory therapies based on the pleiotropic cytokine CXCL12, a platform exclusively licensed from Massachusetts General Hospital in 2013 and protected by 8 patent families. The company's product strategy is organized into two franchises: a cellular line (Vicapsys/ViCapsyn) encapsulating cells in alginate polymers containing CXCL12 to create immune-privileged environments for transplanted islet cells, and a non-cellular line (ViBrin) using CXCL12 formulated in bioabsorbable polymers for wound healing and adhesion prevention. Its lead clinical candidate, ViCapsyn, targets Type 1 diabetes through stem-cell-derived β-islet transplantation without systemic immunosuppression; ViBrin is aimed at diabetic foot ulcers (post-debridement) and at preventing post-peritoneal surgical adhesions, the latter being an indication with no approved pharmacological therapy.

The company is incorporated in Florida with a contact address in Cumming, Georgia, operates with 1-10 employees, and has reported no commercial revenue. Its primary scientific counterparty is Massachusetts General Hospital (platform licensor and origin of the underlying research, including the 1999 discovery of fugetaxis by founder Dr. Mark Poznansky). JDRF has co-funded and co-developed the diabetes allotransplant program. Capitalization is modest: a 2023 SEC exempt offering raised $330,000 (with a 2018 raise of $50,000 also disclosed), well below typical preclinical biotech needs, and the company has not announced any institutional venture financing, partnership upfronts, or licensing deals beyond the MGH license. The board was expanded in September 2022 to add cellular therapy and capital-markets expertise, and Federico Pier was named permanent CEO in February 2022 after serving in an interim capacity since August 2020. Vicapsys currently monetizes through potential future licensing/royalty arrangements rather than product sales, and its value proposition rests on enabling islet and other cell transplantation without lifelong immunosuppression.

Name

Vicapsys

Legal name

Vicapsys Life Sciences, Inc.

Website

https://vicapsys.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Vicapsys Life Sciences is a pre-clinical, publicly traded biotech (OTC: VICP) developing CXCL12-based localized immunomodulatory therapies, including encapsulated islet-cell transplants for Type 1 diabetes and bioabsorbable polymer treatments for diabetic foot ulcers and post-surgical adhesions, with technology exclusively licensed from Massachusetts General Hospital.

Ownership category

akta.pro rank

Product category

Immunomodulatory Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industries

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Cell-based therapeutics
• Diabetes treatment
• Immunomodulatory therapy
• Alginate encapsulation
• Biopharmaceutical development

Headquarters

HQ city

Suwanee

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Biopharmaceutical Development: The company is focused on developing CXCL12-based therapies for treatment of Type 1 diabetes through islet cell transplantation, diabetic foot ulcers, and post-peritoneal surgery adhesions. Products are in preclinical and clinical development stages. No commercial revenue has been generated as of the available information.

Marketing channels1 record

Core offering

Vicapsys develops CXCL12-based localized immunomodulatory therapies organized into two product lines: cellular therapeutics (Vicapsys™/ViCapsyn™) using alginate-microencapsulated cells that create an immune-privileged environment for transplanted islet cells in Type 1 diabetes, and non-cellular therapeutics (ViBrin™) using CXCL12 formulated in bioabsorbable polymers for diabetic foot ulcer healing and post-surgical adhesion prevention. The platform is exclusively licensed from Massachusetts General Hospital and is currently in preclinical and clinical development.

Product overview

Vicapsys is a biotech company developing CXCL12-based localized immunomodulatory therapies organized into two product lines: cellular (Vicapsys™) containing living cells, and non-cellular (ViBrin™) using CXCL12 formulated in bioabsorbable polymers. The lead clinical candidate ViCapsyn™ employs stem cell-derived islet cells encapsulated with CXCL12 in an alginate matrix for treatment of Type 1 diabetes, while ViBrin™ addresses diabetic foot ulcers and post-surgical adhesions.

Differentiator

Problem solved

Functional benefit

Brands

• ViCapsyn: Cell-based therapeutics containing CXCL12 for treatment of Type 1 diabetes through β-islet stem cell transplantation
• ViBrin

Products and services

• Vicapsys™ Cell-based therapeutics containing CXCL12 encapsulated in alginate polymers, designed to create an immune-protected environment for transplanted cells without requiring systemic immunosuppression. CXCL12 repulses Effector T cells and recruits Regulatory T cells, permits survival of transplanted cells, promotes anti-inflammatory and anti-fibrotic processes, and promotes angiogenesis.
• ViBrin™ CXCL12-based therapeutics without cells, with CXCL12 complexed into bioabsorbable polymers and applied to incision sites or wound areas. Designed for acceleration of diabetic foot ulcer healing and prevention of post-surgical adhesions in abdominal/pelvic surgeries. Addresses a market where no approved pharmacological intervention exists for adhesion prevention.
• ViCapsyn™ Allogenic human stem cells differentiated into β-cells, transplanted in a matrix of alginate containing CXCL12 for the treatment of Type 1 diabetes without systemic immunosuppression. Designed to enable long-term survival of transplanted islet cells with fibrosis-free maintenance up to 6 months post-transplantation in primate studies.

Quantifiable outcome

• Stem cell derived islets maintained glucose responsiveness and endocrine hormone expression for 6 months in primate studies.
• +2 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Massachusetts General Hospital (MGH)coreStrategic or Co-development Partner · 1 January 2013Platform technology exclusively licensed from Massachusetts General Hospital in 2013. The core patents were filed and the company was formed following this licensing agreement. MGH serves as the origin of the CXCL12-based platform technology.
• JDRF (Juvenile Diabetes Research Foundation)coreStrategic or Co-development PartnerJDRF has funded and partnered in the development of the diabetes allotransplant program. The company notes that its cell transplantation program for Type 1 Diabetes was funded by and developed in partnership with JDRF. JDRF is the leading global organization funding Type 1 diabetes research.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Novartis: Operates one of the leading commercial cell therapy franchises (Kymriah CAR-T) and has active interest in encapsulated cell therapy and regenerative medicine. Represents the type of strategic acquirer Vicapsys would need to attract to commercialize its platform.
• Organogenesis: Commercial-stage regenerative medicine company with approved skin substitute and wound care products, including for diabetic foot ulcers. Comparable to the ViBrin DFU indication, but at commercial scale with established distribution.
• MiMedx Group: Sells amniotic membrane-based wound care products (e.g., EpiFix) for diabetic foot ulcers and other chronic wounds. Targets the same DFU indication as ViBrin and competes for the same prescribing clinicians.
• Sanofi: Major diabetes care incumbent with broad Type 1 and Type 2 diabetes franchises and active cell therapy/innovation interests. Operates broadly in the disease areas Vicapsys targets but at vastly greater scale and breadth.
• Vertex Pharmaceuticals: Acquired Semma Therapeutics and is advancing VX-880, a stem-cell-derived islet cell therapy for Type 1 diabetes, into clinical trials. Operates in the same T1D cell-therapy space but with vastly greater resources and a broader therapeutic portfolio.

Direct peers

• Sigilon Therapeutics: Develops encapsulated cell therapies (Shielded Living Therapeutics) using modified alginate biomaterials to deliver therapeutic cells without immunosuppression. Closely comparable encapsulation-based platform technology and product strategy to Vicapsys.
• FzioMed: Develops bioresorbable adhesion barrier products (Oxiplex, Adherus) for post-surgical adhesion prevention. Directly comparable to the ViBrin adhesion prevention indication, though using a different mechanism.
• ViaCyte: Clinical-stage cell therapy developer of encapsulated stem-cell-derived islet cells for Type 1 diabetes. Directly comparable to Vicapsys's ViCapsyn program in modality, target indication, and immune-encapsulation approach.

Emerging players

• Seraxis: Preclinical-stage company developing stem-cell-derived islet cells for Type 1 diabetes, with proprietary encapsulation approaches. Comparable target indication and product format to Vicapsys's ViCapsyn.

Others

• Celtaxsys: Earlier-stage MGH spinout (also founded by Dr. Mark Poznansky) developing immunomodulatory therapeutics. Comparable by founding lab and scientific mechanism, though currently focused on cystic fibrosis rather than T1D.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vicapsys